Alzheimer's patients may benefit from cell therapy

Image
IANS New York
Last Updated : Mar 17 2018 | 3:20 PM IST

Transplanting a special type of neuron into the Alzheimer's brain can restore memory and other cognitive functions, a study has revealed that can lead to new treatment.

The brain relies on the perfect coordination of many elements to function properly. If one of those elements is affected, it affects the entire body.

In Alzheimer's disease, damage to specific neurons alter brainwave rhythms causing a loss of cognitive functions.

The inhibitory interneuron is particularly important for managing brain rhythms, said researchers at Gladstone Institutes in the US.

The scientists uncovered the therapeutic benefits of genetically improved interneurons by transplanting them into the brain of a mouse model of Alzheimer's disease.

The inhibitory interneuron controls complex networks between neurons, allowing them to send signals to one another in a harmonised way. They are responsible for the instructions given by the brain.

An imbalance between these two types of neurons creates disharmony and is seen in multiple neurological and psychiatric disorders, including Alzheimer's disease, epilepsy, schizophrenia and autism.

Researchers noted in Alzheimer's mouse models that the inhibitory interneurons do not work properly.

However, when the enhanced by adding a protein called Nav1.1, the interneurons with enhanced function are able to overcome the toxic diseased environment and restore brain function.

They are then able to properly control the activity of excitatory cells and restore brain rhythms, the researchers noted.

"We took advantage of the fact that transplanted interneurons can integrate remarkably well into new brain tissues, and that each interneuron can control thousands of excitatory neurons," said Jorge Palop, Assistant Professor at the University of California in San Francisco, the US.

"These properties make interneurons a promising therapeutic target for cognitive disorders associated with brain rhythm abnormalities and epileptic activity," Palop added, in a paper published in the journal Neuron.

--IANS

ng/rt/and/in

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 17 2018 | 3:16 PM IST

Next Story